<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04632069</url>
  </required_header>
  <id_info>
    <org_study_id>103800</org_study_id>
    <secondary_id>P20GM109040</secondary_id>
    <nct_id>NCT04632069</nct_id>
  </id_info>
  <brief_title>NAC +taVNS in IDM Who Are Poor Oral Feeders</brief_title>
  <official_title>N-acetylcysteine Plus Transcutaneous Vagus Nerve Stimulation in Infants of Diabetic Mothers Who Fail Oral Feeding</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of General Medical Sciences (NIGMS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Infants of diabetic mothers who are failing to learn oral feeding by term age equivalence&#xD;
      have greater CNS oxidative stress, which interact to predict poor neuroplasticity response to&#xD;
      transcutaneous vagus nerve stimulation paired with oral feeding. We propose treating the&#xD;
      oxidative stress in IDM infants prior to initiating taVNS, with an FDA-approved antioxidant&#xD;
      (N-acetylcysteine, NAC) to improve CNS oxidative stress, which in turn regulates expression&#xD;
      of many genes including BDNF, that may enhance motor learning.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our group has recently conducted a first-in-infants pilot trial of pairing transcutaneous&#xD;
      auricular vagus nerve stimulation (taVNS) with feeding to assist learning oromotor skills. We&#xD;
      are enrolling preterm and HIE infants who are failing to learn oral feeds and clinically&#xD;
      determined to need a G-tube. In preliminary data, taVNS paired with one or two daily feedings&#xD;
      for 2 weeks resulted in 50% of infants attaining full feeds and avoiding G-tube.&#xD;
&#xD;
      A notable number of non-responders were infants of diabetic mothers (IDM) exposed to poor&#xD;
      glucose control during pregnancy, all of whom required a G-tube. Uncontrolled maternal&#xD;
      hyperglycemia is associated with increased systemic and neuro-inflammation, CNS oxidative&#xD;
      stress, DNA damage, and worse neonatal outcomes compared to infants of euglycemic mothers. In&#xD;
      neonatal animal models, hyperglycemia has been shown to decrease BDNF, alter long-term&#xD;
      synaptogenesis and hippocampal neurochemistry, with ongoing CNS oxidative stress and&#xD;
      inhibition of the cortical neuronal plasticity required for learning. In our pilot trial of&#xD;
      taVNS-paired feeding, CNS glutathione concentrations (GSH), a MR spectroscopy (MRS) marker of&#xD;
      oxidative stress, had significant interaction with IDM in predicting outcome, strongly&#xD;
      suggesting that ongoing CNS oxidative stress contributes to neuropathology in IDMs failing&#xD;
      oral feeding.&#xD;
&#xD;
      NAC is an FDA-approved antioxidant that is safe and crosses the blood brain barrier,&#xD;
      increasing CNS GSH. NAC reduces CNS oxidative stress, enhances learning and provides a&#xD;
      neuroprotective effect after brain injury in our and others neonatal HI and neuroinflammatory&#xD;
      animal models. Both GSH and BDNF enhance neuroplasticity. Therefore, we hypothesize that&#xD;
      pre-treatment with NAC in IDMs who are failing oral feeding, followed by taVNS-paired&#xD;
      feeding, will decrease oxidative stress induced by maternal hyperglycemia and IDM-associated&#xD;
      brain injury, and increase response to taVNS-paired feeding rehabilitation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 12, 2021</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>We will obtain parental consent, and then administer NAC 100mg/kg loading dose, followed by 75mg/kg q 6h via nasogastric tube, started 4 days prior to taVNS-paired feeding and continued for a total of 14 days. We will perform pharmacokinetics of oral NAC, and MRIs prior to, after 3-4 days of NAC, and after taVNS treatment period.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Co-investigator analyzing MRI data will be blinded to timing of MRI scan and dose</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Daily oral feeding volumes</measure>
    <time_frame>20 days</time_frame>
    <description>ml/kg/d of oral feeds, slope of change of oral feeding volumes before and after NAC + taVNS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Metabolite concentrations in basal ganglia</measure>
    <time_frame>14 days</time_frame>
    <description>[GSH] and other CNS metabolites by MRS before, and after 3-4 days of NAC and after NAC+taVNS treatment</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Diffusion Kurtosis Imaging (DKI)</measure>
    <time_frame>14 days</time_frame>
    <description>DKI metrics in white matter tracts before and after NAC+taVNS treatment</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Infant of Diabetic Mother</condition>
  <condition>Oxidative Stress</condition>
  <condition>Vagus Nerve Stimulation</condition>
  <condition>Feeding Disorders</condition>
  <arm_group>
    <arm_group_label>NAC + taVNS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NAC will be given via nasogastric tube (n,g.) 100mg/kg loading dose, then 75mg/kg/dose n.g. q 6h, administered 1h before a feed, for a total of 14 days. taVNS will be administered to left ear during active sucking with 2 daily feedings starting after 4 days of NAC, continuing for 10 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>N acetyl cysteine + vagus nerve stimulation</intervention_name>
    <description>NAC x 14 days, taVNS x 10 days</description>
    <arm_group_label>NAC + taVNS</arm_group_label>
    <other_name>NAC, Acetadote, taVNS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Infants of diabetic mothers who are failing oral feeding, &gt;39weeks gestation at&#xD;
             enrollment, who are clinically stable, on minimal respiratory support (nasal cannula&#xD;
             or room air), and clinical team has determined are G-tube candidates&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unstable infants or those requiring positive pressure respiratory support&#xD;
&#xD;
          -  Infants &lt;39 weeks gestation at enrollment&#xD;
&#xD;
          -  Major unrepaired congenital anomalies or anomalies that limit feeding volumes&#xD;
&#xD;
          -  Infants with cardiomyopathy&#xD;
&#xD;
          -  Repeated episodes of autonomic instability (apnea/ bradycardia) not self resolving&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>5 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dorothea Jenkins, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dorothea Jenkins, MD</last_name>
    <phone>843-792-2112</phone>
    <email>jenkd@musc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dorothea Jenkins, MD</last_name>
      <phone>843-792-4341</phone>
      <email>jenkd@musc.edu</email>
    </contact>
    <investigator>
      <last_name>Dorothea D. Jenkins, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bashar Badran, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mark George, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sandra Garner, PharmD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert Turner, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sonal Bhatia, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patricia Coker-Bolt, OT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Badran BW, Jenkins DD, Cook D, Thompson S, Dancy M, DeVries WH, Mappin G, Summers P, Bikson M, George MS. Transcutaneous Auricular Vagus Nerve Stimulation-Paired Rehabilitation for Oromotor Feeding Problems in Newborns: An Open-Label Pilot Study. Front Hum Neurosci. 2020 Mar 18;14:77. doi: 10.3389/fnhum.2020.00077. eCollection 2020.</citation>
    <PMID>32256328</PMID>
  </reference>
  <reference>
    <citation>Badran BW, Jenkins DD, DeVries WH, Dancy M, Summers PM, Mappin GM, Bernstein H, Bikson M, Coker-Bolt P, George MS. Transcutaneous auricular vagus nerve stimulation (taVNS) for improving oromotor function in newborns. Brain Stimul. 2018 Sep - Oct;11(5):1198-1200. doi: 10.1016/j.brs.2018.06.009. Epub 2018 Jun 30.</citation>
    <PMID>30146041</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>November 12, 2020</study_first_submitted>
  <study_first_submitted_qc>November 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2020</study_first_posted>
  <last_update_submitted>August 12, 2021</last_update_submitted>
  <last_update_submitted_qc>August 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of South Carolina</investigator_affiliation>
    <investigator_full_name>Dorothea D. Jenkins</investigator_full_name>
    <investigator_title>Professor of Pediatrics</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fetal Diseases</mesh_term>
    <mesh_term>Pregnancy in Diabetics</mesh_term>
    <mesh_term>Feeding and Eating Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>will share de-identified data after publication of results</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>after publication of results</ipd_time_frame>
    <ipd_access_criteria>written request of PI</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

